scholarly article | Q13442814 |
P356 | DOI | 10.1016/S0960-9776(11)70316-2 |
P698 | PubMed publication ID | 22015286 |
P2093 | author name string | Ian Smith | |
Anastasia Constantinidou | |||
P2860 | cites work | High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller | Q24641848 |
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer | Q27851549 | ||
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. | Q34433731 | ||
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer | Q34496969 | ||
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. | Q36901398 | ||
Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. | Q37123529 | ||
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy | Q37163797 | ||
Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer | Q43250044 | ||
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer | Q43270036 | ||
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial | Q46736552 | ||
Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas | Q48111542 | ||
Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. | Q50773376 | ||
Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)]. | Q53048159 | ||
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers | Q59487524 | ||
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM | Q84592604 | ||
P921 | main subject | chemotherapy | Q974135 |
P304 | page(s) | S158-61 | |
P577 | publication date | 2011-10-01 | |
P1433 | published in | The Breast | Q7719928 |
P1476 | title | Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer? | |
P478 | volume | 20 Suppl 3 |
Q44593682 | Complete Radiologic Response of Bulky Cerebral Metastases From Newly Diagnosed HER2-Positive Breast Cancer to Upfront Trastuzumab-Based Chemotherapy. |
Q38132237 | Pertuzumab for the treatment of metastatic breast cancer |
Q48294650 | Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study |
Q28081124 | Treatment of early-stage HER2+ breast cancer-an evolving field |
Search more.